In Depth 10 Jun 2024
ASCO 2024: The latest advances in oncology clinical trials
Biotechs from all over the country as well as other parts of the world showcased recent pipeline advancements in oncology clinical trials at ASCO 2024.
In Depth
- Latest Posts
In Depth 6 Jun 2024
CRISPR: A promising path to treating blindness
Rigorous research, which has been going on for more than a decade now, suggests that CRISPR could treat genetic diseases including blindness.
In Depth 5 Jun 2024
Evolving standards of care: new treatments for cervical cancer
New treatments for cervical cancer aim to broaden therapeutic options, and improve current standards of care for patients.
In Depth 3 Jun 2024
The biggest private biotech investments in May 2024
The companies Uniquity Bio, AltruBio, and BridgeBio Oncology Therapeutics bagged the biggest private biotech investments in May 2024.
In Depth 30 May 2024
Covalent biologics: a new class of drugs on the horizon
The field of covalent biologics has made headway recently, as the only biotech in the space has bagged $100 million to move its pipeline to the clinic.
In Depth 23 May 2024
Is prime editing ready for prime time?
Prime editing, a more advanced version of CRISPR/Cas9 technology, has been greenlit by the FDA to begin the first-ever clinical trial for this technology.
ADVERTISEMENT
ADVERTISEMENT
In Depth 22 May 2024
The undruggable cancer target: KRAS inhibitors move ahead in the clinic
Uncover the promise of KRAS inhibitors in cancer treatment, as evidenced by a $200 million investment in BridgeBio’s spinout.
In Depth 15 May 2024
Drugs for IgA nephropathy on the rise in the clinic
As we observed IgA Nephropathy Awareness Day on May 14th, let us take a look at ongoing clinical trials for drugs that aim to make patient lives better.
In Depth 13 May 2024
New antidepressants: tackling treatment resistant depression
Take a look at how new antidepressants can more effectively tackle treatment resistant depression compared to more traditional treatments.
In Depth 9 May 2024
BTK inhibitors: can these drugs tackle cancer and autoimmunity?
BTK inhibitors were first approved over a decade ago to treat a rare blood cancer. Now, they are in the running to treat a host of autoimmune diseases.
In Depth 9 May 2024
The biggest private biotech investments in April 2024
The companies Xaira Therapeutics, Metsera, and Obsidian Therapeutics bagged the biggest private biotech investments in April 2024.
In Depth 8 May 2024
New treatment for pulmonary hypertension: what biotech holds in store?
While it has been about managing pulmonary hypertension’s symptoms for a long time, new treatments are adressing the root of the disease.
ADVERTISEMENT
